EU Pharmaceutical Legislation Impact: Biosimilar Market Entry & Competition 2027

Key Takeaways

The European Medicines Agency (EMA) region has entered a new era for pharmaceutical market access following the December 2025 political agreement on revised EU pharmaceutical legislation. The legislative framework introduces structural changes—an expanded Bolar exemption and revised market exclusivity periods—that will fundamentally accelerate biosimilar and generic market entry starting in 2027. Why it matters: These regulatory reforms directly address the competitive timeline for biosimilar developers and will reshape the landscape for affordable biologic therapies across Europe. The changes signal the European Union's commitment to expediting patient access to cost-effective biosimilars while intensifying competition among manufacturers.

Drug Overview

This analysis addresses the regulatory and market dynamics of biosimilars as a therapeutic class, rather than a single drug entity. Biosimilars are biological medicinal products highly similar to an already-approved reference biologic drug, with no clinically meaningful differences in efficacy or safety. The biosimilar class encompasses monoclonal antibodies, fusion proteins, recombinant cytokines, and other complex biologics approved under abbreviated regulatory pathways that demonstrate comparability to reference products. Biosimilars serve as cost-effective alternatives to originator biologic therapies across oncology, immunology, endocrinology, and other therapeutic areas, with approval facilitated by the EMA's established comparability framework.

Regulatory Context

The revised EU pharmaceutical legislation, politically agreed upon in December 2025, introduces two critical regulatory mechanisms designed to accelerate biosimilar market entry. First, an expanded Bolar exemption permits biosimilar and generic developers to conduct regulatory, HTA, pricing/reimbursement, and procurement activities during the market exclusivity period of the reference product—previously restricted activities that delayed competitive entry. Second, revised market exclusivity periods shorten the window during which originator biologics enjoy market protection, enabling biosimilars to enter the market faster following patent expiry.

These changes take effect beginning in 2027, creating a compressed timeline for biosimilar developers to complete European Medicines Agency (EMA) approval, HTA submissions to bodies such as the National Institute for Health and Care Excellence (NICE) in the United Kingdom, Gemeinsamer Bundesausschuss (G-BA) in Germany, Haute Autorité de Santé (HAS) in France, and Agenzia Italiana del Farmaco (AIFA) in Italy, and subsequent pricing/reimbursement negotiations with national health authorities. The regulatory pathway does not alter the EMA's existing comparability requirements but rather removes temporal barriers to parallel preparation of market access dossiers.

Market Impact: Accelerated Biosimilar Entry and Intensified Competition

The expanded Bolar exemption and revised market exclusivity periods will fundamentally reshape competitive dynamics in the biosimilar market. Compared with the current regulatory environment, where biosimilar developers must wait for originator patent expiry before initiating HTA submissions and reimbursement negotiations, the revised framework enables simultaneous preparation of multiple market access components. This compression of pre-launch timelines is expected to reduce the lag between EMA approval and market availability, particularly in major EU member states with centralized HTA and reimbursement processes. [Source: European Medicines Agency]

For biosimilar manufacturers, the legislative changes create both opportunities and strategic imperatives. Companies can now initiate HTA dossier preparation, health economic modeling, and procurement discussions with hospital pharmacy groups and national healthcare systems during the reference product's exclusivity period. This early engagement with payers—particularly NICE, G-BA, HAS, and AIFA—allows biosimilar developers to align evidence generation with payer requirements and accelerate post-approval reimbursement decisions. The result is a compressed market entry timeline, with multiple biosimilars potentially launching within months rather than years of EMA approval.

Intensified competition is expected to drive biosimilar pricing downward across the EU5 and broader European markets. Earlier market entry enables multiple biosimilar competitors to establish market share simultaneously, reducing the window for any single manufacturer to capture premium pricing. This dynamic is particularly significant for high-cost originator biologics in oncology, rheumatology, and gastroenterology, where biosimilar uptake directly impacts healthcare budgets. Payers and procurement bodies will benefit from expanded choice and competitive pricing, while originator manufacturers face accelerated revenue erosion post-patent expiry.

What to watch next: The EMA and national HTA bodies will need to establish operational frameworks for managing concurrent regulatory, HTA, and reimbursement submissions beginning in 2027, ensuring that compressed timelines do not compromise evidence review quality or patient safety.

Future Outlook: Implications for Stakeholders and Patient Access

The revised EU pharmaceutical legislation is expected to deliver long-term benefits across the healthcare ecosystem. Patients will gain faster access to affordable biosimilar alternatives, reducing out-of-pocket costs and expanding treatment options within constrained healthcare budgets. Healthcare systems in Germany, France, Italy, Spain, and the United Kingdom will benefit from competitive pricing pressure, enabling greater utilization of biosimilars in hospital and ambulatory settings and freeing resources for other therapeutic priorities.

For biosimilar developers, the regulatory changes create a more level competitive landscape. Smaller manufacturers and emerging biosimilar companies can now prepare comprehensive market access strategies in parallel with regulatory review, reducing the capital and operational barriers to EU market entry. This democratization of biosimilar development timelines may increase the number of market entrants and accelerate innovation in manufacturing efficiency and cost reduction.

Challenges remain, however. The compressed timelines require biosimilar manufacturers to invest in parallel regulatory, HTA, and reimbursement expertise earlier in development, increasing upfront costs. National healthcare systems must adapt procurement and formulary management processes to accommodate simultaneous biosimilar launches. Regulatory bodies including the EMA will face increased workload managing concurrent submissions, requiring resource planning and process optimization.

Strategic recommendations for biosimilar developers include: (1) initiating HTA evidence generation during Phase III clinical trials, well before patent expiry; (2) engaging early with NICE, G-BA, HAS, and AIFA to understand payer-specific requirements and evidence standards; (3) developing differentiated market access strategies tailored to each EU member state's reimbursement framework; and (4) investing in manufacturing scale-up and supply chain readiness to support rapid post-approval market entry.

Frequently Asked Questions

References

1. European Commission. Political agreement on revised EU pharmaceutical legislation finalizing expanded Bolar exemption and revised market exclusivity periods. December 2025.

1. European Medicines Agency. EMA approval. Accessed 2026-04-23.